Unlocking the power of precision medicine for FL patients
The Precision Medicine Programme (PMP) is a ground-breaking initiative, mobilising the Follicular Lymphoma (FL) patient community to fuel a targeted acceleration in FL research and clinical development.
Delivering the PMP will accelerate finding a cure
Our aim is to unlock the power of bespoke, precision medicine for Follicular Lymphoma patients – transforming treatment options and accelerating us on our path to a cure.
The PMP will leverage real-world data, including biological data to promote new directions in FL research and will drive biopharma and industry drug development.
The core impact of PMP is to understand each patient’s unique biology and use this to predict the best option for therapy based on that information. By delivering the PMP, we expect an array of scientific findings to improve the care and longevity of every FL patient
The PMP objectives
Together with our partners, we engaged with clinicians, researchers, life sciences and patients across the globe to identify through consensus the top unmet needs in FL, and therefore the key objectives of the PMP:
• Understand better the biology of FL (which can vary from patient to patient)
• Optimise treatment regimens & sequencing – knowing what FL treatments and in which order will give the best results
• Profile and predict treatment toxicity
• Develop surrogate endpoints (an indicator used to predict if a treatment works)
• Generate real-world data